Video

The Evolving Treatment Landscape in SCLC

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Beth Sandy, MSN, CRNP, thoracic oncology nurse practitioner, Abramson Cancer Center, University of Pennsylvania, discusses the evolving treatment landscape in small cell lung cancer (SCLC). 

Single-agent immunotherapy had shown encouraging data in the second- and third-line settings. However, the emergence of chemoimmunotherapy in the frontline setting has revolutionized the treatment landscape, says Sandy.

In 2019, the FDA approved the combination of atezolizumab (Tecentriq), carboplatin, and etoposide for the frontline treatment of patients with extensive-stage SCLC. Moreover, in March 2020, the FDA approved the combination of durvalumab (Imfinzi) and etoposide and either carboplatin or cisplatin in the same setting.

On June 15, 2020, the FDA grated an accelerated approval to lurbinectedin (Zepzelca) for patients with metastatic SCLC who have disease progression following platinum-based chemotherapy. Each FDA approval is a welcome addition to the armamentarium, Sandy concludes. 

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD